Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam, Mary Ann Anderson, Christiane Pott, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 13, pp. 1211-1223
Open Access | Times Cited: 379

Showing 1-25 of 379 citing articles:

Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1913
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain, Michael J. Keating, Philip A. Thompson, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 22, pp. 2095-2103
Open Access | Times Cited: 457
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Mérino, Gemma L. Kelly, Guillaume Lessène, et al.
Cancer Cell (2018) Vol. 34, Iss. 6, pp. 879-891
Open Access | Times Cited: 265
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 45-64
Closed Access | Times Cited: 255
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Peter Hillmen, Andy C. Rawstron, Kristian Brock, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 30, pp. 2722-2729
Open Access | Times Cited: 241
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Preetesh Jain, Michael Wang
American Journal of Hematology (2019) Vol. 94, Iss. 6, pp. 710-725
Open Access | Times Cited: 226
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Tingyu Wen, Jinsong Wang, Yuankai Shi, et al.
Leukemia (2020) Vol. 35, Iss. 2, pp. 312-332
Open Access | Times Cited: 207
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor, Juraj Bodo, Brian T. Hill, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 196
Update on mantle cell lymphoma
Kami J. Maddocks
Blood (2018) Vol. 132, Iss. 16, pp. 1647-1656
Open Access | Times Cited: 192
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal, Yih-Chih Chan, Constantine S. Tam, et al.
Nature Medicine (2018) Vol. 25, Iss. 1, pp. 119-129
Closed Access | Times Cited: 179
The Mitochondrion as an Emerging Therapeutic Target in Cancer
Katherine G. Roth, Isa Mambetsariev, Prakash Kulkarni, et al.
Trends in Molecular Medicine (2019) Vol. 26, Iss. 1, pp. 119-134
Open Access | Times Cited: 161
Bruton Tyrosine Kinase Inhibitors
Jan A. Burger
The Cancer Journal (2019) Vol. 25, Iss. 6, pp. 386-393
Open Access | Times Cited: 146
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 142
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Andrew D. Zelenetz, Leo I. Gordon, Julie Chang, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 11, pp. 1218-1230
Open Access | Times Cited: 131
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
Blood (2022) Vol. 139, Iss. 21, pp. 3148-3158
Open Access | Times Cited: 96
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain, Michael Wang
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 638-656
Closed Access | Times Cited: 94
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Aqu Alu, Hong Lei, Xuejiao Han, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 86
Mantle-Cell Lymphoma
Jamés O. Armitage, Dan L. Longo
New England Journal of Medicine (2022) Vol. 386, Iss. 26, pp. 2495-2506
Closed Access | Times Cited: 80
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule, Martin Dreyling, André Goy, et al.
Haematologica (2018) Vol. 104, Iss. 5, pp. e211-e214
Open Access | Times Cited: 142
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin, Stephanie Grabow, Matthew S. Davids
Blood (2018) Vol. 132, Iss. 12, pp. 1248-1264
Open Access | Times Cited: 137
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams, Sean Clark-Garvey, Pierluigi Porcu, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 136
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Sheau Wen Lok, James R. Whittle, François Vaillant, et al.
Cancer Discovery (2019) Vol. 9, Iss. 3, pp. 354-369
Open Access | Times Cited: 127
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
Toby A. Eyre, Harriet S. Walter, Sunil Iyengar, et al.
Haematologica (2018) Vol. 104, Iss. 2, pp. e68-e71
Open Access | Times Cited: 117
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra, et al.
The Lancet Haematology (2018) Vol. 6, Iss. 1, pp. e38-e47
Open Access | Times Cited: 111
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Simone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Haematologica (2019) Vol. 105, Iss. 6, pp. 1604-1612
Open Access | Times Cited: 108
Page 1 - Next Page

Scroll to top